J Neurosurg. 2021 Aug 13;136(2):456-463. doi: 10.3171/2021.2.JNS204420. Print 2022 Feb 1.
The 5-factor modified frailty index (mFI-5) is a practical tool that can be used to estimate frailty by measuring five accessible factors: functional status, history of diabetes, chronic obstructive pulmonary disease, congestive heart failure, and hypertension. The authors aimed to validate the utility of mFI-5 for predicting endovascular and microsurgical treatment outcomes in patients with unruptured aneurysms.
A prospectively maintained database of consecutive patients with unruptured aneurysm who were treated with clip placement or endovascular therapy was used. Because patient age is an important predictor of treatment outcomes in patients with unruptured aneurysm, mFI-5 was supplemented with age to create the age-supplemented mFI-5 (AmFI-5). Associations of scores on these indices with major complications (symptomatic ischemic or hemorrhagic stroke, pulmonary embolism, pneumonia, or surgical site infection requiring reoperation) were evaluated. Validation was carried out with the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database (2006-2017).
The institutional database included 275 patients (88 underwent clip placement, and 187 underwent endovascular treatment). Multivariable analysis of the surgical cohort showed that major complication was significantly associated with mFI-5 (OR 2.0, p = 0.046) and AmFI-5 (OR 1.9, p = 0.028) scores. Significant predictive accuracy for major complications was provided by mFI-5 (c-statistic = 0.709, p = 0.011) and AmFI-5 (c-statistic = 0.720, p = 0.008). The American Society of Anesthesiologists Physical Status Classification System (ASA) provided poor discrimination (area under the curve = 0.541, p = 0.618) that was significantly less than that of mFI-5 (p = 0.023) and AmFI-5 (p = 0.014). Optimal relative fit was achieved with AmFI-5, which had the lowest Akaike information criterion value. Similar results were obtained after equivalent analysis of the endovascular cohort, with additional significant associations between index scores and length of stay (β = 0.6 and p = 0.009 for mFI-5; β = 0.5 and p = 0.003 for AmFI-5). In 1047 patients who underwent clip placement and were included in the NSQIP database, mFI-5 (p = 0.001) and AmFI-5 (p < 0.001) scores were significantly associated with severe postoperative adverse events and provided greater discrimination (c-statistic = 0.600 and p < 0.001 for mFI-5; c-statistic = 0.610 and p < 0.001 for AmFI-5) than ASA score (c-statistic = 0.580 and p = 0.003).
mFI-5 and AmFI-5 represent potential predictors of procedure-related complications in unruptured aneurysm patients. After further validation, integration of these tools into clinical workflows may optimize patients for intervention.
改良五因素衰弱指数(mFI-5)是一种实用的工具,可以通过测量五个可及的因素:功能状态、糖尿病史、慢性阻塞性肺疾病、充血性心力衰竭和高血压来评估衰弱。作者旨在验证 mFI-5 对未破裂动脉瘤患者血管内和显微手术治疗结果的预测价值。
使用了连续接受未破裂动脉瘤夹闭或血管内治疗的患者的前瞻性维护数据库。由于患者年龄是未破裂动脉瘤患者治疗结果的重要预测因素,因此 mFI-5 补充了年龄以创建年龄补充的 mFI-5(AmFI-5)。评估这些指数评分与主要并发症(症状性缺血性或出血性中风、肺栓塞、肺炎或需要再次手术的手术部位感染)之间的关联。使用美国外科医师学会国家手术质量改进计划(NSQIP)数据库(2006-2017 年)进行验证。
机构数据库包括 275 例患者(88 例行夹闭术,187 例行血管内治疗)。手术队列的多变量分析显示,主要并发症与 mFI-5(OR 2.0,p = 0.046)和 AmFI-5(OR 1.9,p = 0.028)评分显著相关。mFI-5(c 统计量=0.709,p =0.011)和 AmFI-5(c 统计量=0.720,p =0.008)为主要并发症提供了显著的预测准确性。美国麻醉医师协会身体状况分类系统(ASA)的判别能力较差(曲线下面积=0.541,p=0.618),明显低于 mFI-5(p=0.023)和 AmFI-5(p=0.014)。AmFI-5 的相对拟合度最佳,其 Akaike 信息准则值最低。对血管内队列进行等效分析后得到了类似的结果,指数评分与住院时间之间存在显著的关联(mFI-5:β=0.6,p=0.009;AmFI-5:β=0.5,p=0.003)。在接受夹闭术且纳入 NSQIP 数据库的 1047 例患者中,mFI-5(p=0.001)和 AmFI-5(p<0.001)评分与严重术后不良事件显著相关,并提供了更高的判别力(mFI-5:c 统计量=0.600,p<0.001;AmFI-5:c 统计量=0.610,p<0.001)比 ASA 评分(c 统计量=0.580,p=0.003)。
mFI-5 和 AmFI-5 是未破裂动脉瘤患者与手术相关并发症的潜在预测因子。经过进一步验证,将这些工具整合到临床工作流程中可能会优化患者的干预效果。